Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. Mk-4618
2. N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
1. 1190389-15-1
2. Krp-114v
3. Gemtesa
4. Mk-4618
5. (s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide
6. M5tse03w5u
7. C26h28n4o3
8. Mk4618
9. (6s)-n-(4-(((2s,5r)-5-((r)-hydroxyphenylmethyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
10. Pyrrolo(1,2-a)pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-n-(4-(((2s,5r)-5-((r)-hydroxyphenylmethyl)-2-pyrrolidinyl)methyl)phenyl)-4-oxo-, (6s)-
11. Beova
12. Pyrrolo[1,2-a]pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-, (6s)-
13. Vibegron [usan]
14. Vibegron [usan:inn]
15. Unii-m5tse03w5u
16. Vibegronum
17. Beova (tn)
18. Mk 4618
19. Vibegron (jan/usan)
20. Vibegron [inn]
21. Vibegron [jan]
22. Vibegron [who-dd]
23. Vibegron [orange Book]
24. Chembl2107826
25. Schembl11985457
26. Gtpl10100
27. Dtxsid40152299
28. Chebi:142418
29. Ex-a3390
30. Bdbm50146154
31. Mfcd28502057
32. At23148
33. Compound 7 [pmid: 26709102]
34. Db14895
35. Hy-19933
36. Cs-0016926
37. D10433
38. A903957
39. Q27283524
40. (6s)-4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-pyrrolo[1,2-a]pyrimidine-6-carboxamide
41. (6s)-4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxopyrrolo[1,2-a]pyrimidine-6-carboxamide
42. (6s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl(methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-
43. (6s)-n-[4-({(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide
44. (6s)-n-[4-[[(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6h-pyrrolo[1,2-a]pyrimidine-6-carboxamide
Molecular Weight | 444.5 g/mol |
---|---|
Molecular Formula | C26H28N4O3 |
XLogP3 | 1.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 444.21614077 g/mol |
Monoisotopic Mass | 444.21614077 g/mol |
Topological Polar Surface Area | 94 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 782 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Vibegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Vibegron selectivity for beta-3 adrenergic receptors is >9000 times higher than for 1AR or 2AR. Vibegron improves clinical symptoms of overactive bladder by increasing bladder capacity without affecting bladder contraction. It significantly increases the functional bladder volume in a dose-dependent manner, which results in prolongation of the interval between voids. In clinical studies, vibegron inhibited detrusor bladder contractions in a concentration-dependent manner, reduced voiding pressure, and increased bladder compliance. In Japanese clinical studies comprising patients with overactive bladder, vibegron significantly improved the frequency of micturition, urgency, and urgency incontinence episodes.
Absorption
The mean Tmax is 1-3 hours. Steady-state concentrations are achieved within 7 days of once-daily dosing.
Route of Elimination
In a radiolabeled drug study, approximately 59% of the radiolabeled dose was recovered in feces, in which 54% of that amount was in the unchanged parent drug form. About 20% of the radioactivity was recovered in urine, in which 19% of the amount was in the unchanged form.
Volume of Distribution
The mean apparent volume of distribution is 6304 L. The average blood-to-plasma concentration ratio is 0.9. According to tissue distribution studies in animals, vibegron does not penetrate the blood-brain barrier, suggesting limited potential for CNS toxicity in humans.
Clearance
There is limited information on the clearance rate of vibegron.
In vitro, CYP3A4 is the main enzyme responsible for the metabolism of vibegron, which plays a minor role in the elimination of vibegron. Two predominant metabolic pathways are oxidation and glucuronidation to form two oxidative metabolites and three glucuronide metabolites. Metabolites have not been fully characterized.
The terminal plasma half-life ranges from 60 to 70 hours. The effective half-life is 30.8 hours.
Overactive bladder is characterized by symptoms of urge urinary incontinence, urgency, and urinary frequency. Bladder filling and emptying are regulated by the coordinated communication between sympathetic and parasympathetic systems. Bladder filling occurs via parasympathetic inhibition and the sympathetic hypogastric nerve releasing norepinephrine, which acts on beta-adrenergic receptors responsible for mediating detrusor muscle relaxation. Symptoms of overactive bladder are thought to be caused by the deterioration of the sensory connections between the bladder, spinal cord and brain, leading to changes in the lower urinary tract and abnormal bladder sensations of the urge to void at small bladder volumes. Beta-3 adrenergic receptors (3ARs) are expressed in the kidneys and lower urinary tract, including ureters, urethra, prostate, and bladder. Vibegron is a selective agonist at 3AR. One vibegron binds to the receptor, 3AR is stimulated and undergoes a conformation change and activates adenylyl cyclases (AC), which promotes the formation of cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP concentration leads to the activation of cAMP-dependent protein kinase A (PKA), which subsequently phosphorylates myosin light chains that are responsible for inhibiting the interaction of actin with myosin dependent on calcium calmodulin complex. In clinical trials, vibegron increased cAMP levels in a dose-proportional manner. There is evidence that 3AR agonists may also work via sensory mechanisms without directly affecting detrusor muscle motor function.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40275
Submission : 2024-08-01
Status : Active
Type : II
NDC Package Code : 75877-0008
Start Marketing Date : 2023-05-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-07-31
Pay. Date : 2024-06-13
DMF Number : 39538
Submission : 2024-03-21
Status : Active
Type : II
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2024-11-07
Registration Number : 434-69-ND
Manufacturer Name : Ami Lifesciences Private Limited
Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi – 391 450, Dist : Vadodara, Gujarat State, India
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-11-12
Pay. Date : 2024-09-24
DMF Number : 40333
Submission : 2024-09-27
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-08-16
Pay. Date : 2024-07-19
DMF Number : 40068
Submission : 2024-07-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40275
Submission : 2024-08-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-07-31
Pay. Date : 2024-06-13
DMF Number : 39538
Submission : 2024-03-21
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-16
Pay. Date : 2024-07-19
DMF Number : 40068
Submission : 2024-07-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-11-12
Pay. Date : 2024-09-24
DMF Number : 40333
Submission : 2024-09-27
Status : Active
Type : II
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2024-10-22
Pay. Date : 2024-09-26
DMF Number : 40304
Submission : 2024-09-24
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2024-11-07
Registration Number : 434-69-ND
Manufacturer Name : Ami Lifesciences Private Lim...
Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi – 391 45...
Registrant Name : Jeil Pharmaceutical Co., Ltd.
Registration Date : 2022-10-31
Registration Number : Su216-24-ND
Manufacturer Name : Sumitomo Chemicals Co., Ltd....
Manufacturer Address : 3750, Azajuhachicho, Maki, Ampachicho, Ampachi-Gun, Gifu 503-0125, Japan
About the Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities ar...
About the Company : Ami Lifesciences, established in 2006, is one of the fastest growing API manufacturing companies in India. Specializing in cardiovascular, anti-diabetic, CNS, and respiratory thera...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...
About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...
About the Company : Hope Chem is dedicated to manufacturing, marketing, and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals since the year 2010. Current...
About the Company : Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemist...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Obgemsa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Pierre Fabre Overactive Bladder Med Wins Approval
Details : Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.
Brand Name : Obgemsa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2024
Details:
Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Sumitomo Pharma’s Vibegron Supplemental NDA Accepted By FDA
Details : Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2024
Details:
Obgemsa (vibegron) is a beta-3 adrenergic agonist indicated for treating overactive bladder symptoms, including urge incontinence and urinary urgency.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Obgemsa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2024
Pierre Fabre Receives Positive CHMP Opinion for OBGEMSA™ in Overactive Bladder
Details : Obgemsa (vibegron) is a beta-3 adrenergic agonist indicated for treating overactive bladder symptoms, including urge incontinence and urinary urgency.
Brand Name : Obgemsa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2024
Details:
Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2023
Details:
KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the Compound.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sumitomo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 06, 2023
Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 06, 2023
Details:
GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Admini...
Details : GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2022
Details:
Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Pierre Fabre
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 05, 2022
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Pierre Fabre
Deal Size : $75.0 million
Deal Type : Licensing Agreement
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercial...
Details : Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 05, 2022
Details:
In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of O...
Details : In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2022
Details:
Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB).
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details : Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB).
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Details:
The Therapeutics and Clinical Risk Management paper points out that in international phase 3 EMPOWUR trial, treatment with GEMTESA was associated with significant improvements compared with placebo.
Lead Product(s): Vibegron
Therapeutic Area: Urology Brand Name: Gemtesa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details : The Therapeutics and Clinical Risk Management paper points out that in international phase 3 EMPOWUR trial, treatment with GEMTESA was associated with significant improvements compared with placebo.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2022
(1R,2R)-2-amino-6-(4-nitrophenyl)-1-phenylhex-5- y...
CAS Number : 1628836-08-7
End Use API : Vibegron
About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...
(6S)-4,6,7,8-tetrahydro-4- oxo-Pyrrolo[1,2- a]pyri...
CAS Number : 1190392-22-3
End Use API : Vibegron
About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...
Sodium(S)-4-oxo-4,6,7,8- tetrahydropyrrolo[1,2- a]...
CAS Number : 1421271-01-3
End Use API : Vibegron
About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMi...
CAS Number : 1190392-22-3
End Use API : Vibegron
About The Company : Accel Pharmtech, LLC is one of the world’s leading pharmaceutical companies that manufactures and provides their clients and partners with cataloged chemicals...
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMi...
CAS Number : 1190392-22-3
End Use API : Vibegron
About The Company : Hangzhou Hairui Chemical Co., Ltd. is located in the Zhongheng Century Science and Technology Park in Hangzhou, Zhejiang. It is an excellent manufacturer of org...
(1R,2R)-2-Amino-6-(4-nitrophenyl)-1-phenylhex-5-yn...
CAS Number : 1628836-08-7
End Use API : Vibegron
About The Company : JieJie Group Co., Ltd. is a pharmaceutical and chemical enterprise for research and production, it was built in 2009. Our core business is custom synthesis and ...
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMi...
CAS Number : 1190392-22-3
End Use API : Vibegron
About The Company : Jinan Shangbo Pharmaceutical Co., Ltd is a high-tech enterprise that specializes in the R&D, production, and sales of pharmaceutical intermediates and fine chem...
(1R,2R)-2-Amino-6-(4-nitrophenyl)-1-phenylhex-5-yn...
CAS Number : 1628836-08-7
End Use API : Vibegron
About The Company : Jinan Shangbo Pharmaceutical Co., Ltd is a high-tech enterprise that specializes in the R&D, production, and sales of pharmaceutical intermediates and fine chem...
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMi...
CAS Number : 1190392-22-3
End Use API : Vibegron
About The Company : Taizhou Volsen Chemical Co., Ltd. is professional in R&D, producing and marketing Pharmaceutical raw materials, pharmaceutical intermediates in China. VOLSEN co...
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMi...
CAS Number : 1190392-22-3
End Use API : Vibegron
About The Company : Zhejiang Eazy Pharmchem Co., Ltd. which was established since from 1998, has been actively developing specialty products for APIs, Intermediates, and Fine chemi...
Regulatory Info : RX
Registration Country : USA
Brand Name : GEMTESA
Dosage Form : TABLET;ORAL
Dosage Strength : 75MG
Packaging :
Approval Date : 2020-12-23
Application Number : 213006
Regulatory Info : RX
Registration Country : USA
RLD : Yes
TE Code :
Brand Name : GEMTESA
Dosage Form : TABLET;ORAL
Dosage Strength : 75MG
Approval Date : 2020-12-23
Application Number : 213006
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Global Sales Information
Market Place
Reply
15 Nov 2023
Reply
02 Jun 2023
Reply
05 May 2023
Reply
27 Mar 2023
Reply
17 May 2022
Reply
27 Oct 2021
Reply
07 Sep 2021
Reply
19 Apr 2021
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Vibegron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vibegron, including repackagers and relabelers. The FDA regulates Vibegron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vibegron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Vibegron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Vibegron supplier is an individual or a company that provides Vibegron active pharmaceutical ingredient (API) or Vibegron finished formulations upon request. The Vibegron suppliers may include Vibegron API manufacturers, exporters, distributors and traders.
click here to find a list of Vibegron suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Vibegron DMF (Drug Master File) is a document detailing the whole manufacturing process of Vibegron active pharmaceutical ingredient (API) in detail. Different forms of Vibegron DMFs exist exist since differing nations have different regulations, such as Vibegron USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Vibegron DMF submitted to regulatory agencies in the US is known as a USDMF. Vibegron USDMF includes data on Vibegron's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vibegron USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Vibegron suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Vibegron Drug Master File in Korea (Vibegron KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vibegron. The MFDS reviews the Vibegron KDMF as part of the drug registration process and uses the information provided in the Vibegron KDMF to evaluate the safety and efficacy of the drug.
After submitting a Vibegron KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vibegron API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Vibegron suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vibegron as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vibegron API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vibegron as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vibegron and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vibegron NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vibegron suppliers with NDC on PharmaCompass.
Vibegron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vibegron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vibegron GMP manufacturer or Vibegron GMP API supplier for your needs.
A Vibegron CoA (Certificate of Analysis) is a formal document that attests to Vibegron's compliance with Vibegron specifications and serves as a tool for batch-level quality control.
Vibegron CoA mostly includes findings from lab analyses of a specific batch. For each Vibegron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vibegron may be tested according to a variety of international standards, such as European Pharmacopoeia (Vibegron EP), Vibegron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vibegron USP).
LOOKING FOR A SUPPLIER?